Role of p21-activated kinases in thyroid cancer
p21 激活激酶在甲状腺癌中的作用
基本信息
- 批准号:10377551
- 负责人:
- 金额:$ 36.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseAcuteBRAF geneBindingCell LineCell ProliferationCell divisionCellsCentrosomeCessation of lifeChronicClinicComplexDataDiagnosisDiseaseDistant MetastasisGene Expression ProfileGoalsHumanI131 isotopeIn VitroIn complete remissionIndolentKRAS2 geneKnock-inMEK inhibitionMEKsMalignant NeoplasmsMalignant neoplasm of thyroidMediatingMethodsMitosisMitotic ActivityModelingMolecularMutateMutationOutcomePapillary thyroid carcinomaPathway interactionsPatientsPhosphorylationPlayPrognosisPublishingRas/RafRegulationReportingResearchResistanceResistance developmentRoleSamplingSignal TransductionSignaling MoleculeSystemTaxonomyTestingTherapeuticThyroid GlandTissuesWorkbasecancer cellcell growthcell motilityimprovedin vivoinducible gene expressioninhibitorknock-downmelanomamembermortalitymouse modelmutantnovelnovel therapeuticsoverexpressionp21 activated kinasep21-activated kinase 1patient derived xenograft modelprotein complexresponsesynergismtherapeutic evaluationtherapeutic targettherapy resistanttumortumor progressiontumorigenesis
项目摘要
Patients with progressive metastatic papillary thyroid cancer (PTC) have a poor prognosis. Despite advances in developing new therapies complete responses have been elusive and non-durable responses are the best reported outcomes. The presence of gross local invasion and distant metastases are two predictors of death from PTC. We have focused on defining key regulators of these features in an effort to identify novel targets to improve treatment. We identified that the p21 activated kinase (PAK) signaling is activated in the invasive fronts of aggressive PTCs and determined that it regulated human thyroid cancer cell motility and proliferation in vitro. Because of the association between BRAF activation and tumor aggressiveness we analyzed the relationship between these two signaling molecules. We demonstrated that PAK activity was highly regulated by BRAF and that BRAF knock down inhibited PAK activity. Moreover, this effect was independent of MEK. We subsequently identified that PAK physically interacts with BRAF both overexpression and endogenous systems and that the complex occurs in mitosis consistent with a role in regulation cell division and growth. We have shown in vivo that acute activation of BRAF V600E in the thyroid is associated with increased levels of phosphorylated PAK. Finally, we have identified acquired mutations in upstream regulators of PAK in tumor samples from patients who developed resistance to BRAF inhibition. These data point to PAK being a critical downstream target of BRAF which plays an important functional role in PTC progression for tumors with RAS/RAF/ERK pathway activation. The hypotheses of this project is that PAK is a critical signaling node downstream of BRAF involved in thyroid cancer tumorigenesis and progression in vivo; that the mechanism of the interaction can be elucidated, and that it can be exploited to develop improved primary and secondary therapies for patients with progressive thyroid cancer and other patients with BRAF-mutated tumors.
进行性转移性甲状腺乳头状癌(PTC)患者预后不良。尽管在开发新疗法方面取得了进展,但完全缓解一直难以实现,非持久缓解是报告的最佳结局。局部浸润和远处转移是PTC死亡的两个预测因素。我们专注于定义这些特征的关键调节因子,以确定新的靶点来改善治疗。我们发现p21激活激酶(PAK)信号在侵袭性PTC的侵袭性前沿被激活,并确定它在体外调节人甲状腺癌细胞的运动和增殖。由于BRAF激活与肿瘤侵袭性之间的联系,我们分析了这两种信号分子之间的关系。我们证明PAK活性受BRAF高度调节,BRAF敲低抑制PAK活性。此外,这种作用不依赖于MEK。我们随后确定PAK与BRAF过表达和内源性系统物理相互作用,并且该复合物发生在有丝分裂中,与调节细胞分裂和生长的作用一致。我们已经在体内证明甲状腺中BRAF V600 E的急性激活与磷酸化PAK水平的增加相关。最后,我们在对BRAF抑制产生耐药性的患者的肿瘤样本中鉴定了PAK上游调节因子的获得性突变。这些数据表明PAK是BRAF的关键下游靶标,BRAF在RAS/RAF/ERK通路激活的肿瘤的PTC进展中起重要的功能作用。该项目的假设是PAK是BRAF下游的一个关键信号节点,参与体内甲状腺癌肿瘤发生和进展;可以阐明相互作用的机制,并且可以利用它来开发用于进行性甲状腺癌患者和其他BRAF突变肿瘤患者的改善的主要和次要治疗。
项目成果
期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matthew D Ringel其他文献
Matthew D Ringel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matthew D Ringel', 18)}}的其他基金
RCAN 1.4 metastasis suppressor in thyroid cancer
RCAN 1.4 甲状腺癌转移抑制因子
- 批准号:
9973560 - 财政年份:2020
- 资助金额:
$ 36.76万 - 项目类别:
RCAN 1.4 metastasis suppressor in thyroid cancer
RCAN 1.4 甲状腺癌转移抑制因子
- 批准号:
10604328 - 财政年份:2020
- 资助金额:
$ 36.76万 - 项目类别:
RCAN 1.4 metastasis suppressor in thyroid cancer
RCAN 1.4 甲状腺癌转移抑制因子
- 批准号:
10400004 - 财政年份:2020
- 资助金额:
$ 36.76万 - 项目类别:
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve Health
俄勒冈州立大学临床和转化科学中心:推进当今的发现以改善健康
- 批准号:
10414809 - 财政年份:2018
- 资助金额:
$ 36.76万 - 项目类别:
The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE
俄亥俄州立大学和 MD 安德森癌症中心甲状腺癌孢子
- 批准号:
8741949 - 财政年份:2013
- 资助金额:
$ 36.76万 - 项目类别:
Developing Combination Therapies for Medullary Thyroid Cancer
开发甲状腺髓样癌的联合疗法
- 批准号:
8588547 - 财政年份:2013
- 资助金额:
$ 36.76万 - 项目类别:
The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE
俄亥俄州立大学和 MD 安德森癌症中心甲状腺癌孢子
- 批准号:
8548721 - 财政年份:2013
- 资助金额:
$ 36.76万 - 项目类别:
Integrated Clinicopathology and Biorespository Core
综合临床病理学和生物仓库核心
- 批准号:
8588551 - 财政年份:2013
- 资助金额:
$ 36.76万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 36.76万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 36.76万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 36.76万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 36.76万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 36.76万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 36.76万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 36.76万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 36.76万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 36.76万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 36.76万 - 项目类别:
Operating Grants